





10/522525

1/21





10/522525

3/21




FIG 6

4/21







FIG 7

5/21



10/522525

6/21



7/21

10/522525

Fig11






Fig12



10/522525

8/21

FIG. 13



9 / 21




Fig. 14

10/522525

10/21




Fig. 15

11 / 21




Fig. 16

12 / 21




Fig. 17 BEST AVAILABLE COPY

10/522525

13/21




Fig. 18

BEST AVAILABLE COPY

10/522525

14 / 21




Fig. 19

BEST AVAILABLE COPY

10/522525

15/21




Fig. 20

BEST AVAILABLE COPY

10/522525





Fig. 21

BEST AVAILABLE COPY

10/522525

17/21

Formulation Studies with 1.0% PD Solution



BEST AVAILABLE COPY

FIG 22A

10/522525

18/21




FIG 225

BEST AVAILABLE COPY

10/522525

19/21




FIG 23A

BEST AVAILABLE COPY

10/522525

20/21




FIG 23C

EST AVAILABLE COPY

10/522525

21/21




FIG 23C

BEST AVAILABLE COPY